This HTML5 document contains 96 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n8http://www.rxlist.com/cgi/generic3/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00607/identifier/pubchem-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/mesh/concept/
n21http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00607/identifier/pubchem-substance/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00607/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n27http://bio2rdf.org/drugbank:
n23http://linked.opendata.cz/resource/drugbank/drug/DB00607/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n26http://linked.opendata.cz/resource/drugbank/drug/DB00607/identifier/chemspider/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00607/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n13http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n9http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00607/identifier/wikipedia/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00607/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00607/identifier/kegg-compound/
n28http://linked.opendata.cz/ontology/sukl/drug/
n29http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00607/identifier/pdb/

Statements

Subject Item
n2:DB00607
rdf:type
n3:Drug
n3:description
A semi-synthetic antibiotic related to penicillin. [PubChem]
n3:dosage
n4:271B5534-363D-11E5-9242-09173F13E4C5 n4:271B5535-363D-11E5-9242-09173F13E4C5 n4:271B5536-363D-11E5-9242-09173F13E4C5 n4:271B5539-363D-11E5-9242-09173F13E4C5 n4:271B553A-363D-11E5-9242-09173F13E4C5 n4:271B553B-363D-11E5-9242-09173F13E4C5 n4:271B553C-363D-11E5-9242-09173F13E4C5 n4:271B553D-363D-11E5-9242-09173F13E4C5 n4:271B553E-363D-11E5-9242-09173F13E4C5 n4:271B553F-363D-11E5-9242-09173F13E4C5 n4:271B5540-363D-11E5-9242-09173F13E4C5 n4:271B5541-363D-11E5-9242-09173F13E4C5 n4:271B5542-363D-11E5-9242-09173F13E4C5 n4:271B5537-363D-11E5-9242-09173F13E4C5 n4:271B5538-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.
n3:indication
For the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs.
n3:manufacturer
n21:271B552B-363D-11E5-9242-09173F13E4C5 n21:271B552C-363D-11E5-9242-09173F13E4C5 n21:271B552A-363D-11E5-9242-09173F13E4C5 n21:271B552F-363D-11E5-9242-09173F13E4C5 n21:271B552D-363D-11E5-9242-09173F13E4C5 n21:271B552E-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00607 n27:DB00607
dcterms:title
Nafcillin
adms:identifier
n16:Nafcillin n17:8982 n18:46508100 n19:NFN n20:PA450576 n22:C07250 n23:0781-3128-92 n24:DB00607 n25:7447 n26:8634
n3:mechanismOfAction
Penicillinase-resistant penicillins exert a bactericidal action against penicillin-susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall.
n3:packager
n21:271B5527-363D-11E5-9242-09173F13E4C5 n21:271B5528-363D-11E5-9242-09173F13E4C5 n21:271B5526-363D-11E5-9242-09173F13E4C5 n21:271B5529-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Nafcillin is primarily eliminated by nonrenal routes, namely hepatic inactivation and excretion in the bile.
n3:synonym
Nafcilline (2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Naphcillin (2-Ethoxy-1-naphthyl)penicillin (2-Ethoxy-1-naphthalenyl)penicillin Nafcilina 6-(2-Ethoxy-1-naphthamido)penicillanic acid Nafcillinum
n3:toxicity
Serious toxicity is unlikely following large doses of nafcillin. Acute ingestion of large doses of nafcillin may cause nausea, vomiting, diarrhea and abdominal pain. Acute oliguric renal failure and hematuria may occur following large doses.
n3:proteinBinding
89.9 ±1.5%
n3:salt
n13:hasConcept
n14:M0014418
foaf:page
n8:nafcillin.htm n9:nafcillin.html
n3:IUPAC-Name
n6:271B5547-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B554D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B554C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B5549-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B554A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B554B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B5545-363D-11E5-9242-09173F13E4C5 n6:271B555D-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B5543-363D-11E5-9242-09173F13E4C5 n6:271B5546-363D-11E5-9242-09173F13E4C5 n6:271B555E-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B5544-363D-11E5-9242-09173F13E4C5
n28:hasATCCode
n29:J01CF06
n3:H-Bond-Acceptor-Count
n6:271B5553-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B5554-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B554E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B554F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B5551-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B5550-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B5552-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Staphylococcus aureus Enteric bacteria and other eubacteria
n3:casRegistryNumber
147-52-4
n3:category
n3:containedIn
n10:271B5530-363D-11E5-9242-09173F13E4C5 n10:271B5533-363D-11E5-9242-09173F13E4C5 n10:271B5531-363D-11E5-9242-09173F13E4C5 n10:271B5532-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B5559-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B555B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B555C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B5558-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B5557-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B555A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B5548-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B5555-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B5556-363D-11E5-9242-09173F13E4C5